Top Markets
Coin of the day
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
Rang in Aktien #39565
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Aktienkurs
$0.003084
Marktkapitalisierung
$434.03K
Veränderung (1 Tag)
-7.14%
Veränderung (1 Jahr)
-89.24%
Land
BE
Handel Oxurion N.V. (OXUR)

Kategorie

Dividendenrendite-Verlauf für Oxurion N.V. (OXUR)
Dividendenrendite (TTM) von Oxurion N.V. (Aktienkürzel: OXUR) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Oxurion N.V. (OXUR) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber